BioPharmSignal logoBioPharmSignal

Biotech News

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immutep Limited (IMMP)Immutep LimitedCompany update

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), dated 12 October 2026 (US Eastern Time), confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).

Related news

IMMPImmutep Limited2026-10-14 12:00 EST

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

IMMPImmutep Limited2026-09-30 12:00 EST

Immutep Receives ~A$0.86 Million R&D Tax Incentive

GERNGeron2026-10-19 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CMPXCompass Therapeutics2026-10-14 20:30 EST

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-10-02 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-10-02 11:00 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-10-01 21:10 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-09-25 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Immutep Limited

Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.

Recent company news

IMMPImmutep Limited2026-10-14 12:00 EST

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

IMMPImmutep Limited2026-10-13 12:00 EST

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement

IMMPImmutep Limited2026-09-30 12:00 EST

Immutep Receives ~A$0.86 Million R&D Tax Incentive

IMMPImmutep Limited2026-09-21 12:00 EST

Change to American Depositary Share Ratio

IMMPImmutep Limited2026-09-11 12:00 EST

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

Stock data

Close
3.28 USD
Market cap
61.31M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States